Orebro University Hospital

Örebro se-701 85

2 studies enrolling now · 7 studies all time

What they study most

Anemia, Coronary Artery Disease, Ischemic Stroke, Leukemia, Myelofibrosis, Neovascularization, Post- Essential Thrombocythemia Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Primary Myelofibrosis, Prostate Cancer

Studies at this site

• A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib — Recruiting now
• International Registry for Men With Advanced Prostate Cancer (IRONMAN) — Recruiting now
• Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever — Running, not enrolling
• Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib — Completed
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer — Completed
• FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT — Completed
• S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML — Completed